A bright future in aging - HOLD - TP 11,9€
In its IPO on Alternext Paris in mid-July 2015, Biophytis issued 1,672,500 new shares at the price of €6 per share, corresponding to an around €10m capital increase. Following this and profiting from the good performance of the share, Biophytis raised additional funds through the issue of 666,700 new shares to a North American investor for a total of €6m. The company has consequently raised €16m, close to the amount that we felt was needed at the time of the IPO. Biophytis therefore has the means to finance its strategy. Our valuation currently equals €11.9 per share, significantly higher than the IPO price due to a WACC of 13.8% vs. 15.3%. We have a NEUTRAL rating while waiting for the authorisation (expected by mid-2016) for the start of the phase II-b studies.Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.